study question: Can cluster analysis can be used to identify a homogeneous subpopulation of women with polycystic ovarian morphology (PCOM) within a very large population of control women in a non-subjective way?
Introduction
The polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age with prevalence estimates ranging from 6 to 20% depending on the diagnostic criteria applied and the characteristics of the population studied (Norman et al., 2007; March et al., 2010; Yildiz et al., 2012) . Indeed, different diagnostic classifications for PCOS have been proposed among which the Rotterdam classification is now the most widely used (The Rotterdam ESHRE/ ASRM-sponsored PCOS consensus workshop group, 2004 ). This classification has been recently recommended by an international panel of experts to be preferred over other classifications (National Institute of Health, 2012) . It uses three items: hyperandrogenism (HA), oligo/anovulation and polycystic ovarian morphology (PCOM) at ultrasound (U/S). At least two of these items are required for the diagnosis of PCOS.
PCOM is identified by the presence by an excessive follicle number per ovary (FNPO) and/or an increase in ovarian volume (OV) at U/S (Balen et al., 2003) . As emphasized by the Rotterdam consensus conference in 2003, PCOM is insufficient by itself to qualify a woman for the diagnosis of PCOS (The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group, 2004). Indeed, isolated asymptomatic PCOM is a frequent finding in the general population of women of reproductive age with prevalence estimated at 30% in previous studies. However, some controversy has recently arisen about this prevalence (Duijkers and Klipping, 2010; Johnstone et al., 2010; Kristensen et al., 2010) , mainly because the former Rotterdam threshold defining follicle excess, i.e. FNPO ≥ 12 (Balen et al., 2003) , is no longer appropriate if U/S equipment with a transducer frequency ≥8 MHz is used (reviewed in Dewailly et al., 2014) . Indeed, newer U/S technology that affords maximal resolution of ovarian follicles yields much higher values for FNPO (Dewailly et al., 2014) . Additionally, the significance of PCOM in women with regular menstrual cycles and no signs of androgen excess is debated. For some authors, it is nothing but a normal variant of ovarian morphology, unrelated to PCOS (Johnstone et al., 2010) . For others, PCOM may represent the milder end of the PCOS phenotype spectrum but disagreement persists about the unique meaning of this finding (Ng et al., 2006; Mortensen et al., 2009; Catteau-Jonard et al., 2012; Rosenfield et al., 2012) .
Beside these complex issues, the presence of women with PCOM alone in the general population raises also the question as to whether these women should be excluded or not from the control groups when establishing reference intervals and decision threshold values for various parameters used to characterize PCOS (Dewailly et al., 2014) . The problem is how to identify such women if there is no consensus about the appropriate threshold for FNPO. This difficult issue has been recently addressed by using cluster analysis, a statistical multivariate classification procedure used to classify patients in different groups (or clusters) according to different profiles, in a non-subjective manner (Hartigan, 1985; Dewailly, et al. 2011) . In this analysis, two mathematically homogeneous subgroups of asymptomatic women were identified within the control population (Dewailly et al., 2011) . The clustering was primarily based on FNPO, OV and serum anti-Müllerian hormone (AMH) concentration. The subgroup characterized by concomitantly higher values of these variables most likely represented control women with PCOM. Serum AMH concentration was the strongest classifying variable, in line with the observation that an increased level of AMH is an excellent surrogate for the follicle excess in PCOS (Pigny et al., 2003; Laven et al., 2004; Dewailly et al., 2011) .
However, these results were obtained in a relatively small series, with possible referral bias. The objective of the present study was to check whether the results could be replicated in an independent much larger population of non-hyperandrogenic women with regular menstrual cycles. We were also keen to verify whether eliminating asymptomatic PCOM women from controls could increase the sensitivity and specificity of PCOM markers in detecting not only the full-blown PCOS phenotype but also the so-called 'mild' forms of PCOS (Norman et al., 2007) .
Materials and Methods

Study population
In this study, clinical data and laboratory test results derived from the computerized database of the Department of Human Reproduction of Merkur University Hospital (Zagreb, Croatia) were analyzed. All data were prospectively collected and recorded by authorized staff between March 2011 and May 2013. A total of 893 patients referred to Department of Human Reproduction for routine infertility evaluation and treatment were eligible for inclusion in the study. The study population was divided into groups according to their symptoms: (i) the control group (n ¼ 621) included women from infertile couples with regular menstrual cycles and no signs of HA, (ii) the full-blown PCOS group (n ¼ 95) consisted of women who were diagnosed as having PCOS based on the presence of both HA and oligo/amenorrhoea (OA), i.e. women who all met the different classifications for PCOS without having to use U/S criteria and (iii) the mild PCOS group included women with only two items of the Rotterdam classification, i.e. PCOM at U/S according to the FNPO threshold of 12 or more as defined by the Rotterdam consensus and either OA (n ¼ 110) or HA (n ¼ 67) (Balen et al., 2003;  The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group, 2004). Other etiologies of HA and/or OA were carefully ruled out in both PCOS groups.
The exclusion criteria were as follows: women aged ≥40 years, basal serum FSH concentration .12 IU/l, non-classic congenital adrenal hyperplasia, pelvic surgery, hyperprolactinemia, diabetes, thyroid dysfunction, endometriosis, abnormal U/S scan defined as the presence of an ovarian mass or at least one follicle with diameter .9 mm, and use of medications that might have an influence on endocrine profile.
HA was defined as serum total testosterone concentration . 2.7 nmol/l and/or clinically by hirsutism defined as a modified Ferriman -Gallwey (mFG) score .7 (Hatch et al., 1981) . OA was defined as a mean menstrual cycle length (MCL) .35 days in the preceding year.
Identification of asymptomatic polycystic ovaries
Laboratory analyses
Blood samples for the hormone and glucose measurements were taken during the early follicular phase of the menstrual cycle (i.e. between Day 3 and 5 after a spontaneous menstrual cycle or a withdrawal bleeding induced by 100 mg of micronized progesterone vaginally tid for 10 days) between 8:00 and 10:00 h after an overnight fast. All biochemistry analyses were performed in the laboratory accredited according to EN ISO 15189. Estradiol (E 2 ), FSH, LH and testosterone were determined by chemiluminescent immunoassays on an Access w 2 analyzer (Beckman Coulter, Inc., Brea, USA). Insulin concentration was measured using the ADVIA Centaur w XP immunoassay system (Siemens Healthcare Diagnostics, Inc., Tarrytown, USA). Glucose concentration was measured using a hexokinase method (Beckman Coulter, Inc.). The homeostasis model assessment for insulin resistance index (HOMA-IR) was calculated using the formula: HOMA-IR ¼ [fasting insulin (mIU/ml) × fasting glucose (mmol/l)]/22.5 (Matthews et al., 1985) .
Serum AMH concentration was determined using the original protocol of the AMH Gen II ELISA (Beckman Coulter, Inc.). Intra-and inter-assay coefficients of variation demonstrated in our laboratory were 2.5 and 1.5%, respectively. Total (within-laboratory) precision was 3.1% (Clinical and Laboratory Standards Institute, 2005) . All samples for determination of AMH concentration were obtained under the same preanalytical conditions. Aliquots of sera were stored at 2258C to 2208C, for up to 14 days, until analyzed. Since 2011, the laboratory has been regularly and successfully participating in the external quality assessment scheme (UK NEQAS for Peptide Hormones, Edinburgh, UK) for AMH measurements.
Clinical investigation
Physical examination and U/S assessment of ovarian morphology were performed the same day as blood drawing for the laboratory analysis. The number of follicles in each ovary was assessed by a single investigator (M.Š.A.) using a two-dimensional transvaginal probe 5-7 MHz (Toshiba, Nemio, Japan). Ultrasonographic examinations were performed in real-time and all follicles between 2 and 9 mm in diameter were counted by scanning from one margin of ovary to the other in longitudinal cross-sections. Follicular size was measured using the internal diameter of the sonolucent area, and the follicular diameters were calculated as a mean of two perpendicular measurements.
Statistical analyses
All statistical analyses were performed using the Statistical Package for the Social Sciences and SAS software. Statistical significance between mean values was attributed to two-tailed P , 0.05. The results are expressed as median with 5th and 95th percentiles. Comparisons between two groups were performed using the non-parametric Mann-Whitney test and comparisons between more than two groups were performed using the Kruskal-Wallis test and a non-parametric analysis of variance after rank transformation using the methodology suggested by Conover and Iman (1981) . The Bonferroni correction was applied for multiple comparisons in post hoc tests, with significance set at 0.01.
Cluster analysis is a statistical multivariate classification procedure used to classify patients in different groups or clusters according to different profiles (Hartigan, 1985) . These clusters are not defined a priori and are such that individuals in a given cluster are close to each other in the sense of a similar measure and individuals in different clusters tend to be dissimilar. The cluster analysis was based on the k-means method. In this method, the similarity between individuals is measured using the usual Euclidian distance. The homogeneity of clusters was assessed by the squared correlation ratio (R 2 ) which is the ratio of the between-cluster variation and the total variation computed from all the variables. The graphical representation of the R 2 values against the number of clusters was used to choose the most appropriate number of clusters. In addition, the R 2 of each variable was computed in order to determine the most important variables in the identification of clusters. Receiver operating characteristic (ROC) curves were constructed to examine the diagnostic test performance, i.e. the ability to discriminate between groups (Zweig and Campbell, 1993) . Sensitivity (y-axis) against [1 2 specificity (x-axis)] was plotted at each threshold level, and the area under the ROC curve (AUC) was computed by the non-parametric Wilcoxon test. The AUC represents the probability of correctly identifying controls and patients with PCOS. A value of 0.5 means that the result is no better than chance.
Ethical approval
As the present study was retrospective and included only analysis of data obtained from routine clinical and laboratory measurements, the Institutional Review Board approval was not required. However, all patients gave an informed consent at initial consultation for their data to be used for clinical research, statistical reports and/or educational purposes provided that their identity remains protected.
Results
General features of the control and PCOS groups are shown in Table I . All three PCOS phenotypes differed from controls by having significantly higher BMI, waist circumference (WC), MCL, mFG, testosterone, FNPO, AMH, insulin and HOMA-IR. Conversely, age and FSH were significantly lower than in controls. The HA + PCOM group differed from the other two PCOS groups by significantly lower MCL, LH, FNPO and AMH. Serum LH was not different from controls, in contrast to other PCOS groups (Table I) .
Cluster analysis was performed in the control group (n ¼ 621) using age, FNPO, and serum testosterone, FSH, LH and AMH concentrations as classifying variables. Since the models with three or four clusters were not accompanied by a significant increase of total R 2 (see Materials and
Methods section) when compared with the model with two clusters (R 2 ¼ 0.72, 0.76 and 0.62, respectively), we considered that two control subgroups were generated by the analysis, comprising 521 and 100 women (Clusters 1 and 2, respectively). The critical variables for this classification were primarily the serum AMH concentration and then FNPO, with R 2 values of 0.64 and 0.25, respectively. Other variables had much lower R 2 values (,0.06).
Cluster 2 differed from Cluster 1 by having significantly higher mean ranks of FNPO and serum AMH, testosterone and LH concentrations, and significantly lower mean ranks of age and serum FSH concentrations (Table II) . In addition, the MCL and mFG mean ranks were also significantly higher in Cluster 2 than in Cluster 1 (Table II) . No differences were found in BMI, WC, glucose, insulin, E 2 and HOMA-IR mean ranks. AMH was the variable with the least overlap between the two clusters, followed by FNPO (Fig. 1) . The between-cluster overlap was greater with the other variables (Table II) . Given its profile, Cluster 2 was considered to represent asymptomatic women with PCOM and was therefore excluded from our control group.
ROC curve analysis was then performed to test the power of serum AMH value and FNPO to distinguish patients with PCOS from 'pure' controls, i.e. non-PCOM women with regular menstrual cycle and no signs of HA (Cluster 1, n ¼ 521). For that aim, we first used our group of women with full-blown PCOS, thus avoiding selection based on an arbitrary threshold for FNPO (see Materials and Methods section) (n ¼ 95) (Fig. 2) . Table III shows the AUC for FNPO and AMH and the sensitivity and specificity obtained with different thresholds. Our choice was to favor specificity (i.e. at least 90%) without, however, being too detrimental to sensitivity (i.e. at least 80%). We therefore selected thresholds of 28 pmol/l for AMH and of 12 for FNPO as being the best compromise between specificity and sensitivity (Table III) .
Since the best threshold for FNPO in this study was identical to the one that we used initially for definition of PCOM in mild PCOS groups (see Materials and Methods section), we could use these groups to assess diagnostic performance of AMH in distinguishing women with mild PCOS from the non-PCOM controls. The results of the ROC analysis are shown in Table IV . It can be noticed that with the AMH threshold set at 28 pmol/l, we obtained in both mild PCOS groups (PCOM + HA and PCOM + OA, respectively) exactly the same specificity in detecting PCOM as in the full-blown PCOS (97%). On the other hand, sensitivity was slightly lower in the OA + PCOM group and significantly lower in the HA + PCOM group than in the full-blown PCOS group (Fig. 3) .
By comparison of the AUCs after ROC curve analysis, it was demonstrated that exclusion of asymptomatic PCOM women from controls significantly 
Discussion
In this study, we were able to confirm that cluster analysis can identify a subgroup of women with PCOM within a control group of nonhyperandrogenic women with regular menstrual cycles, in a nonsubjective manner (Dewailly et al., 2011) . Serum AMH level appeared to be the most powerful variable in this analysis, as previously reported (Dewailly et al., 2011) . Therefore, we question whether the use of the acronym 'PCOM' that relates only to morphology is still valid. We would rather propose the terms 'polycystic ovary-like (PCO-like) abnormalities', as we did previously . However, we kept 'PCOM' in this report as it is the term internationally agreed upon.
Indeed, beside significant differences in AMH and FNPO, this large series disclosed significant differences between Clusters 1 ('pure' controls) and 2 (PCOM women) for other items. Although being in the normal range, MCL, mFG and serum testosterone and LH concentrations were higher and FSH concentrations were lower in Cluster 2 than in Cluster 1, resembling subtly the endocrine profile observed in genuine PCOS. Such between-cluster differences were not found (only non-significant trends) in Dewailly et al.'s study presumably because their series were too small to yield sufficient statistical power (Dewailly et al., 2011) . Interestingly, no difference in metabolic variables was found, confirming that PCOM do not confer per se any metabolic risk in asymptomatic women (Dewailly at al., 2010; Johnstone et al., 2010) .
At this step, it seemed logical to us to exclude such women from our control group, as recently proposed, before testing the capacity of both Values are medians with 5th -95th percentiles in parentheses.
To convert testosterone to ng/mL, divide by 3.467; to convert E 2 to pg/mL, divide by 3.67; to convert AMH to ng/mL, divide by 7.14; to convert insulin from mIU/l to pmol/l, multiply by 6.945. After post hoc Bonferroni's correction for multiple comparisons (P-value set at 0.01). AMH, anti-Müllerian hormone; FNPO, follicle number per ovary; HOMA-IR, homeostasis model assessment for insulin resistance index; MCL, menstrual cycle length; mFG, modified Ferriman -Gallwey score; WC, waist circumference; E 2 , estradiol; PCOM, polycystic ovarian morphology; OA, oligo/amenorrhoea; HA, hyperandrogenism. FNPO and AMH to distinguish apparently healthy women from patients with genuine PCOS (Dewailly et al., 2011) . By ROC analysis, AMH appeared to be the strongest parameter for identification of PCOS, as previously reported (Dewailly et al., 2011) . The AMH threshold of 28 pmol/l offered the best compromise between sensitivity (84.2%) and specificity (97.5%) for identification of women with PCOS. These figures are among the highest ever reported, and might conceivably be the consequence of the selection of a 'pure control group' derived by the cluster analysis. This study also adds to the previous one (Dewailly et al., 2011) the information that exactly the same serum AMH threshold can be used to confirm with high specificity the diagnosis of PCOS in patients with mild phenotypes despite lower ranges of individual values. However, it must be stressed that sensitivity was lower, especially for the HA + PCOM phenotype. Therefore, the question arises as to whether increased serum AMH concentration should be used instead of PCOM in the Rotterdam classification. If it was the case, this would solve the difficult issue of the great variability in FNPO threshold between recent studies (reviewed in Dewailly et al., 2014) . However, varying AMH thresholds discriminating between women with or without PCOS were also reported (reviewed in Iliodromiti et al., 2013) . The between-study comparison of AMH thresholds is difficult as they were derived from data using different assay configurations and different inclusion criteria for the control and PCOS populations (Dewailly et al., 2011; Eilertsen et al., 2012; Rosenfield et al., 2012; Homburg at al., 2013) . In our study, all AMH results were obtained using the original protocol of the Beckman Coulter AMH Gen II assay (reference A79765). This explains why our threshold of 28 pmol/l differed from that previously found using the same approach but using the Immunotech AMH assay ( Beckman Coulter, Marseille, France; reference A16507; Dewailly et al., 2011) . Recently, the Beckman Coulter company has released a new preanalytical protocol yielding higher values that were, however, closely correlated to the former ones (Beckman Coulter, 2013) . In our hands, the AMH results currently obtained using this modified protocol are 2-fold higher than those obtained using the original protocol, with an excellent correlation coefficient (r ¼ 0.989, data not shown). Therefore, we think that this technical issue does not change the conclusions derived from our cluster and ROC analysis since the co-linearity between the AMH values obtained by both protocols was very strong. The main advantages of our study are the very large size of the control population, and homogeneity of the study population with respect to racial, ethnic and geographic origin. There was no selection bias other than being evaluated for infertility treatment. However, this could also be considered as a limitation of the study as these women may not necessarily be a representative sample of the general population.
In conclusion, our goal was not to provide an AMH threshold to be used universally but rather to demonstrate that serum AMH has intrinsically a very high potency to detect women with PCOM within a control group. This allowed us to derive a more homogenous control group and thus setting with better precision a unique threshold that detected all the PCOS phenotypes with high specificity. So far, however, such a threshold remains specific for the method and clinical setting described here. Therefore, only so-called in-house AMH thresholds are to be used until the AMH results are harmonized (Plebani, 2013) . The question then arises as to whether asymptomatic women with PCOM should be excluded from clinical studies in order to get 'pure control groups'. This is an important issue if reference intervals and decision limits are to be determined. Furthermore, if one considers that PCOM in apparently healthy women represents the milder end of the PCOS phenotype spectrum, the detection of such women is fundamental for the correct assignment of subjects within the frame of familial and genetic studies. Although we do demonstrate that AMH has intrinsically a very high discriminatory power for PCOS, due to methodological issues we cannot currently recommend AMH to be used instead of U/S markers of PCOM. When the harmonization of AMH assays is achieved, In bold, best compromise between sensitivity and specificity. 
